argenx Financial Ratios
NASDAQ: ARGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
825.03+6.40 (+0.78%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
argenx ratio analysis
Return on equity reached 17.6%, meaning argenx generated 0.18 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
argenx financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 42.92 | 48.61 | — | — | — | — | — | — |
| Price / sales | — | — | 612.08 | 2,054.79 | 35.97 | 323.81 | 78.05 | 164.90 |
| Price / book | 7.03 | 6.76 | 5.31 | 7.32 | 7.06 | 7.98 | 5.19 | 5.75 |
| Gross margin | — | — | -231.6% | -193.5% | — | — | — | — |
| Operating margin | — | — | -1,196.2% | -7,184.7% | -70.1% | -1,158.1% | -253.5% | -381.0% |
| Net margin | — | — | -830.4% | -7,077.5% | -82.1% | -1,475.3% | -231.0% | -310.2% |
| Free cash flow margin | — | — | -1,185.2% | -8,614.0% | -122.8% | -968.7% | 191.0% | — |
| Return on equity (ROE) | 17.6% | 15.2% | -7.2% | -25.2% | -16.1% | -36.3% | -15.4% | -10.8% |
| Return on assets (ROA) | 14.9% | 13.4% | -6.5% | -22.6% | -14.3% | -26.7% | -11.3% | — |
| Current ratio | 5.23 | 7.29 | 9.75 | 9.18 | 8.44 | 6.26 | 8.58 | — |
| Revenue growth | — | — | 254.4% | -98.0% | 1,105.7% | -47.4% | 265.2% | — |
| EPS growth | 53.1% | — | — | — | — | — | — | — |